Loading clinical trials...
Loading clinical trials...
A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors
Conditions
Interventions
BXQ-350
Locations
2
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Nationwide Children's
Columbus, Ohio, United States
Start Date
April 15, 2019
Primary Completion Date
January 3, 2020
Completion Date
January 17, 2020
Last Updated
July 22, 2021
NCT07213804
NCT07169851
NCT07159659
NCT00026884
NCT06662786
NCT07191730
Lead Sponsor
Bexion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions